Patient characteristics by response at month 12
| . | Total . | Month 12 response . | P value . | |
|---|---|---|---|---|
| CR . | PD/NCR . | |||
| N = 28 (%) . | n = 15 (54%) . | n = 13 (46%) . | ||
| Sex | ||||
| Female | 14 (50) | 7 (47) | 7 (54) | >.99∗ |
| Male | 14 (50) | 8 (53) | 6 (46) | |
| Age at diagnosis, y | ||||
| Median (range) | 64 (37-77) | 67 (47-77) | 61 (37-73) | .14† |
| ≤60 | 10 (36) | 5 (33) | 5 (38) | >.99∗ |
| >60 | 18 (64) | 10 (67) | 8 (62) | |
| Diagnosis | ||||
| DLBCL | 17 (61) | 7 (47) | 10 (77) | .12∗ |
| High-grade B-cell lymphoma, triple hit | 1 (4) | 1 (7) | ||
| PMBCL | 1 (4) | — | 1 (8) | |
| Transformed follicular | 6 (21) | 5 (33) | 1 (8) | |
| Transformed marginal zone | 1 (4) | 1 (7) | — | |
| Transformed SLL | 1 (4) | — | 1 (8) | |
| Transformed Waldenström macroglobulinemia | 1 (4) | 1 (7) | — | |
| Subtype | ||||
| EBV+ | 1 (4) | — | 1 (8) | .55∗ |
| GCB-Type | 10 (36) | 6 (40) | 4 (31) | |
| MYC and BCL2 and/or BCL6 rearrangements “double hit” | 1 (4) | 1 (7) | — | |
| Non-GCB | 10 (36) | 4 (27) | 6 (46) | |
| Triple hit | 1 (4) | 1 (7) | - | |
| Missing | 5 (18) | 3 (20) | 2 (15) | |
| ECOG PS | ||||
| 0 | 10 (36) | 6 (40) | 4 (31) | .87∗ |
| 1 | 15 (54) | 8 (53) | 7 (54) | |
| 2 | 3 (11) | 1 (7) | 2 (15) | |
| Ann Arbor stage | ||||
| I | 3 (11) | 1 (7) | 2 (15) | .59∗ |
| II | 1 (4) | — | 1 (8) | |
| III | 9 (32) | 6 (40) | 3 (23) | |
| IV | 15 (54) | 8 (53) | 7 (54) | |
| Time from Dx to CAR-T, median (range), mo | 20.0 (4.6-121.7) | 39.6 (4.9-121.7) | 14.3 (4.6-98.5) | .013† |
| No. of previous treatments, median (range) | 3 (1-11) | 3 (1-11) | 3 (2-5) | .42† |
| Previous autologous hematopoietic stem cell transplant | ||||
| No | 19 (68) | 8 (53) | 11 (85) | .11∗ |
| Yes | 9 (32) | 7 (47) | 2 (15) | |
| Bridging therapy | ||||
| No | 17 (61) | 9 (60) | 8 (62) | >.99∗ |
| Yes | 11 (39) | 6 (40) | 5 (38) | |
| . | Total . | Month 12 response . | P value . | |
|---|---|---|---|---|
| CR . | PD/NCR . | |||
| N = 28 (%) . | n = 15 (54%) . | n = 13 (46%) . | ||
| Sex | ||||
| Female | 14 (50) | 7 (47) | 7 (54) | >.99∗ |
| Male | 14 (50) | 8 (53) | 6 (46) | |
| Age at diagnosis, y | ||||
| Median (range) | 64 (37-77) | 67 (47-77) | 61 (37-73) | .14† |
| ≤60 | 10 (36) | 5 (33) | 5 (38) | >.99∗ |
| >60 | 18 (64) | 10 (67) | 8 (62) | |
| Diagnosis | ||||
| DLBCL | 17 (61) | 7 (47) | 10 (77) | .12∗ |
| High-grade B-cell lymphoma, triple hit | 1 (4) | 1 (7) | ||
| PMBCL | 1 (4) | — | 1 (8) | |
| Transformed follicular | 6 (21) | 5 (33) | 1 (8) | |
| Transformed marginal zone | 1 (4) | 1 (7) | — | |
| Transformed SLL | 1 (4) | — | 1 (8) | |
| Transformed Waldenström macroglobulinemia | 1 (4) | 1 (7) | — | |
| Subtype | ||||
| EBV+ | 1 (4) | — | 1 (8) | .55∗ |
| GCB-Type | 10 (36) | 6 (40) | 4 (31) | |
| MYC and BCL2 and/or BCL6 rearrangements “double hit” | 1 (4) | 1 (7) | — | |
| Non-GCB | 10 (36) | 4 (27) | 6 (46) | |
| Triple hit | 1 (4) | 1 (7) | - | |
| Missing | 5 (18) | 3 (20) | 2 (15) | |
| ECOG PS | ||||
| 0 | 10 (36) | 6 (40) | 4 (31) | .87∗ |
| 1 | 15 (54) | 8 (53) | 7 (54) | |
| 2 | 3 (11) | 1 (7) | 2 (15) | |
| Ann Arbor stage | ||||
| I | 3 (11) | 1 (7) | 2 (15) | .59∗ |
| II | 1 (4) | — | 1 (8) | |
| III | 9 (32) | 6 (40) | 3 (23) | |
| IV | 15 (54) | 8 (53) | 7 (54) | |
| Time from Dx to CAR-T, median (range), mo | 20.0 (4.6-121.7) | 39.6 (4.9-121.7) | 14.3 (4.6-98.5) | .013† |
| No. of previous treatments, median (range) | 3 (1-11) | 3 (1-11) | 3 (2-5) | .42† |
| Previous autologous hematopoietic stem cell transplant | ||||
| No | 19 (68) | 8 (53) | 11 (85) | .11∗ |
| Yes | 9 (32) | 7 (47) | 2 (15) | |
| Bridging therapy | ||||
| No | 17 (61) | 9 (60) | 8 (62) | >.99∗ |
| Yes | 11 (39) | 6 (40) | 5 (38) | |
DLBCL, Diffuse Large B-cell Lymphoma; Dx, Diagnosis; EBV+, Epstein-Barr Virus; ECOG PS, Eastern Cooperative Oncology Group Performance Status; GCB-type, Germinal center B-cell-like-type; NCR, non-complete response; PMBCL, Primary Mediastinal B-cell Lymphoma; SLL, Small lymphocytic lymphoma.
Fisher exact test.
Wilcoxon rank sum test.